Proptosis clinical trials at UCSD

1 in progress, 0 open to eligible people

Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Sorry, in progress, not accepting new patients
The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).
La Jolla 5363943, California 5332921 and other locations

Last updated: January 2025

Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)